Treatment Information

Common Hormonal Treatment for Early Prostate Cancer May Pose Cardiac Risk

I have been on a vacation but am now resuming publishing pertinent posts. As has been written before, several potential side effects accompany hormonal therapy for prostate cancer. A MedlinePlus e mail received today from the National Institutes of Health (NIH) National Library of Medicine discussed the potential heart risk posed by early hormone suppression more »

Removal of Ipilimumab (Yervoy) in Proposed NCI Clinical Trial Due to Toxicity.

On May 15th, this website posted information about a Phase 1-2 clinical trial sponsored by the National Cancer Institute (NCI) of the National Institutes of Health (NIH). The proposed therapeutic regimen initially consisted of the NCI vaccine Prostvac, and two antibodies, ipilimumab (Yervoy®) and nivolumab (Opdivo®). However, toxic events recently surfaced in the use of more »

If You Are Taking Taxotere for Prostate Cancer, This Blog on Minimizing Hair Loss May Be of Interest.

The Food and Drug Administration (FDA) has cleared a cooling cap—a device designed to reduce hair loss during chemotherapy—for use by patients with any kind of solid tumor. FDA initially cleared the device, the DigniCap® Scalp Cooling System, for patients with breast cancer in 2015. The expanded clearance of DigniCap is for “reducing the frequency more »

A Simplified Guide to the Immune System and How Immunotherapy Can Fight Prostate Cancer

The last post discussed the concept of vaccines for prostate cancer. The second part of the PCF trilogy is an overall simplified view of the immune system, including the various cell types and how they work under both normal and cancerous conditions. This section also describes checkpoint inhibitors and how they are being developed to more »

A Must-Read Cutting-Edge Review of Immunotherapy for Prostate Cancer

I just received an e mail from the Prostate Cancer Foundation (PCF) which consisted of a three-part review of immunotherapy as applied to prostate cancer. The review consists of three parts: a) Immunotherapy, a Vaccine for Prostate Cancer; b) Who’s Who in the Immune System; and c) Immunotherapy and Prostate Cancer. The review is so more »

A Testimonial to Treating a Gene Involved in Metastatic Prostate Cancer

This linked article is an excellent personalized example of treating a man with metastatic prostate cancer and a mutated genetic defect in his BRCA2 gene. He was treated with the PARP inhibitor olaparib which is approved for ovarian cancer. The story itself needs little comment so I urge you to read the following link from more »

One Study Comparing Urinary and Sexual Outcomes for Robotic Prostatectomy Versus Brachytherapy.

 Men with low-risk prostate cancer have similar recurrence-free survival rates when treated with surgical robotic prostatectomy or brachytherapy, but those who received surgery had fewer urinary or sexual problems two years after treatment, a randomized trial in Italy has concluded. The study was recently published in the April 2017 issue of the Canadian Journal of Urology [Claudio et more »

New Cutting-Edge Combination Immunotherapy Clinical Trial Available

Having advanced prostate cancer albeit at an early stage, I, in discussions with my Florida oncologist, had decided to pursue a course of immunotherapy first before using drugs that kill the cancer cells directly. I remembered writing previous website blogs in which several prominent oncologists and urologists recommended treating the cancer with immunotherapies first. I more »

Qiagen to Market AR-V7 Genetic Test That Shows If Prostate Cancer Responds to Enzalutamide (Xtandi) or Abiraterone (Zytiga).

Enzalutamide (Xtandi®) and abiraterone acetate (Zytiga®) are two approved hormone therapies commonly prescribed for men with hormone-resistant advanced prostate cancer. They block the androgen receptor signaling that is essential to the cancer’s growth. Although they represent breakthroughs in metastatic treatment, 20 to 40 percent of patients fail to respond to them.  These men with advanced more »

Yervoy Fails to Shut Down Prostate Cancer But Could Be Used in Combination Therapy

A recent article from Prostate Cancer News Today (April 4th) stated that Yervoy (ipilimumab) showed little benefit when administered to 16 patients awaiting surgery with locally advanced prostate cancer at the University of Texas M.D. Anderson Cancer Center. The study was published in Nature Medicine. Ipilimumab (also known as MDX-101 and MDX-010 and marketed as more »

Hormone Therapy (Androgen Deprivation) Not Found to Increase the Risk of Dementia, Alzheimers.

Recent studies summarized on this website on December 30th, 2015 and November 7th, 2016 concluded that hormonal therapy of prostate cancer was linked to an increase in dementia and Alzheimer’s disease. Now a recent study published in the Journal of Clinical Oncology and summarized in the February 6th, 2017 e mail issue of Prostate Cancer more »

An Available Phase III Trial of ODM-201 in Men with High Risk, Non-Metastatic, Hormone Resistant Prostate Cancer

ODM-201 (also known as BAY-1841788) is a non-steroidal, oral anti-androgen (specifically a full and high-affinity antagonist of the androgen receptor (AR), that is under development by Orion and Bayer Healthcare for the treatment of advanced, hormone-resistant prostate cancer. [An antagonist is a drug (blocking agent) that binds to the cellular receptor for a hormone (e.g. more »

Anxiety May Lead to Un-Necessary Prostate Cancer Treatments

 A new study published in the Journal of Urology suggests that anxiety may prompt prostate cancer patients to opt for potentially unnecessary treatments. The research included more than 1,500 men newly diagnosed with localized prostate cancer. They were more likely to choose surgery and radiation therapy than active surveillance. Active surveillance — also known as more »

A Short Informative Video on Clinical Trials from the Director of the National Institutes of Health

The National Institutes of Health (NIH) of the Department of Health and Human Services (DHHS) sponsors clinical trials related to many diseases and conditions including prostate cancer. (The National Cancer Institute, NCI, is the largest of all the institutes comprising NIH). The director of the NIH, Dr. Francis Collins recently discussed accessing information about these more »

A Great Review of Possible Treatments for Advanced Prostate Cancer

The Prostate Cancer Foundation (PCF) just published an e mail review entitled “When Treatment Stops Working, Blame Resistance.” It describes multiple ways of treating advanced prostate cancer including androgen receptor blockers such as enzalutamide and abiraterone, chemotherapy, targeted drugs such as PARP inhibitors (olaparib and rucaparib), immunotherapy including checkpoint inhibitors, bipolar hormonal therapy, SBRT radiation, more »

Two-drug combination boosts survival in patients with metastatic, hormone-sensitive prostate cancer

Patients with newly diagnosed metastatic, hormone-sensitive prostate cancer gained a dramatic survival benefit with simultaneous initiation of two drugs, rather than delaying the second drug until the cancer began to worsen, according to results of a clinical trial recently published in The New England Journal of Medicine (2015; doi:10.1056/NEJMoa1503747). Patients who underwent six cycles of more »

Two New DNA Cancer Vaccines in Phase 1 and Phase 2 Clinical Trials

Madison Vaccines Incorporated (MVI, see the linked news release), has begun a Phase 1 clinical trial for MVI-118 (pTVG-AR) in men with metastatic prostate cancer who are initiating androgen deprivation (hormonal) therapy (ADT). MVI-118 targets the human androgen receptor, the critical biological target responsible for driving prostate cancer progression and, in many cases, resistance to more »